The People Who Perform These Scans Are Careful About Selling Them
The Society of Cardiovascular Computed Tomography is the professional body for cardiac CT. Its own Choosing Wisely list, published in 2013, includes two items worth reading twice. Do not order calcium scoring to screen low-risk people without symptoms, except those with a family history of premature coronary disease. And do not routinely order coronary CT angiography to screen people without symptoms.
The American College of Cardiology is just as direct: stress testing with imaging, or other advanced non-invasive imaging, should not be part of the initial evaluation of people without cardiac symptoms unless high-risk markers are present. The American College of Radiology is blunt about a different set of tests, rating stress echo, nuclear stress imaging, and cardiac MRI “usually not appropriate” in adults without symptoms at every level of risk, including high. That same document is more favorable to calcium scoring, which it rates “usually appropriate” at intermediate risk.
That mixture is the honest starting point. Not a blanket no. A set of specific yeses inside a general one.
Important: This article is for educational purposes and cannot tell you which test you need. New, worsening, or persistent chest discomfort needs prompt medical attention. Call 911 if you think you may be having an emergency.
What Advanced Cardiac Imaging Actually Covers
Anyone asking whether they need a heart scan is really asking about six different things, and they are not equivalent.
Coronary CT angiography uses dye and a CT scanner to show the arteries directly, including plaque that is not blocking anything yet. Coronary calcium scoring is a shorter, dye-free CT counting calcified plaque only, and it has its own article rather than a paragraph here. Cardiac MRI images the heart muscle. Cardiac PET measures blood flow through it. AI plaque analysis is software that runs on a CT you have already had and reports how much plaque there is and what kind. Whole-body MRI is not a heart test at all, though it gets sold alongside them.
Each answers a different question. None answers the one most people actually have, which is whether they will have a heart attack.
These markers help us identify where we may be able to reduce risk.
What a Scan Can and Cannot Tell You
Changing your risk estimate is not the same as changing your outcome
Three different claims get run together here. Imaging moves your estimated risk, which nobody disputes. It also changes behavior and prescribing, and there is randomized evidence for that. But that it reduces heart attacks, strokes, or deaths in people without symptoms has not been shown in any randomized trial. Keeping those three apart is most of what this subject requires.
What happened when people without symptoms were actually screened
FACTOR-64 randomized 900 people with long-standing diabetes and no heart symptoms. Half were screened by coronary CT, half got routine care. The scans found something in about two thirds, and more than two thirds of that group were sent for additional testing, told to intensify treatment, or both.
At four years there was no difference in death, heart attack, or hospitalization for unstable angina. At a mean of 12.7 years, still no difference. One thing did differ. The screened group had about 70 percent more stents and bypass surgery, 13.3 percent against 7.8 percent.
More testing, more procedures, same outcomes.
The test that does have outcome data, and what it showed
Coronary CT angiography is the exception, and the detail matters. In SCOT-HEART, 4,146 patients attending a chest pain clinic were randomized to standard care with or without a CT. At ten years, coronary death or non-fatal heart attack was lower in the CT group, 6.6 percent against 8.2 percent.
Read the rest of that result too. The benefit was entirely in non-fatal heart attacks, with no difference in death from any cause. No difference in how many had an angiogram, and none in how many got a stent or bypass. PROMISE then randomized 10,003 symptomatic patients to CT or to standard functional testing, and the two produced the same event rate.
So the evidence for coronary CT is real. It is in people with symptoms. And it comes from finding plaque that changes prevention, not blockages that change plumbing.
What It Does NOT Necessarily Mean
- It does not mean these tests are useless. Several answer specific questions well.
- It does not mean more detail is always better. A more sensitive test finds more things that were never going to matter.
- It does not mean a test that predicts risk will also guide treatment. Those are different jobs.
The goal is to understand your complete cardiovascular picture.
Questions to Discuss With Your Physician
These four questions are worth taking with you. The first is the one everything else follows from.
- What decision would this test change? If the answer is none, why are we doing it?
- Is this test recommended for someone with my symptoms and my risk level, or is it being offered because it is available?
- What happens if it finds something incidental and unrelated?
- Is there a cheaper or lower-radiation test that answers the same question?
What Actually Adds Clarity
Imaging earns its place when a specific symptom or a specific unresolved decision makes the result capable of changing what happens next. Four examples where that is true.
Cardiac MRI for heart muscle injury with clear arteries. This is among the cleanest indications in cardiology. Say someone has evidence of injury to the heart muscle but no blocked arteries. Contrast MRI can tell whether the cause is inflammation of the heart or its lining, and current US guidance gives it the strongest class of recommendation.
Cardiac MRI when an echo is inconclusive. Where the heart muscle may be thickened, MRI is recommended if the echo cannot settle the diagnosis or rule out look-alike conditions.
PET or MRI blood flow measurement for symptoms with clear arteries. Where chest pain persists and the arteries look normal, measuring blood flow can identify a small-vessel problem rather than leaving the pain unexplained.
Calcium scoring as a tiebreaker. The 2026 cholesterol guideline recommends it for men from 40 and women from 45 at borderline or intermediate risk, when the decision about lipid-lowering treatment is truly unsettled. It also allows it where the open question is how hard to treat. It is not a test for people who already have established heart disease, and not a way to check whether treatment is working. In someone with an inherited cholesterol disorder, a score of zero settles nothing.
The honest note on radiation and cost
A coronary CT angiogram runs around 7 millisieverts on average, and the spread between centers is wide. The largest worldwide survey, covering 742 centers in 2023, found a median of 7.4 with a middle range of 3.5 to 15.5. Compare that with about 1.2 for a calcium scan, 0.1 for a chest X-ray, and about 3 a year from natural background. Most of the difference came from which center and country did the scan, and newer scanners gave noticeably lower doses, which is worth asking about.
On cost, a directory of 594 advertised self-pay prices puts the median calcium scan at about $113. A coronary CT angiogram costs more, so ask for the price before booking.
Medication may be one part of the strategy. Lifestyle and metabolic optimization remain important regardless.
When Further Cardiovascular Assessment May Be Appropriate
Those four are where imaging earns its place. Here are three things that are usually not worth it for screening.
Usually not worth it for risk screening: carotid intima-media thickness. Still sold by wellness practices. In 2010 US guidance called it reasonable at intermediate risk. By 2013, as the evidence matured, that had dropped to no benefit. The largest pooled analysis covered 45,828 people across 14 cohorts. The net gain in correct classification was 0.8 percent overall and 3.6 percent at intermediate risk.
Be cautious about AI plaque analysis. It is marketed hard, so here are the facts. Every product is FDA cleared through the route showing a device is similar to one already sold, not the route showing it improves health. No randomized trial has shown it improves any patient outcome. The trial designed to test that is still enrolling. Repeat scans of the same person agree on rank order. But the margin on the actual volume is wide, so a small change between two scans may reflect the scan rather than the disease. Medicare’s regional policies pay for it in a chest pain workup, and list screening as non-covered in those words.
Usually not worth it as a screening test: whole-body MRI. Across ten studies and 9,024 people without symptoms, cancer was found in 1.57 percent. In one large population study, about one in three people scanned got an incidental finding that might matter. The American College of Radiology says no documented evidence shows total body screening prolongs life. It warns the findings lead to needless follow-up and expense.
If a practice has recommended one of these to you, the question to bring your physician is what decision the result would change. A complete cardiovascular risk assessment draws on several measures rather than one.
Where CoCardio® Fits
Detect Early. Protect Fully. Connect Deeply.
There is a version of preventive cardiology that sells scans, and one that works out which question needs answering first. The second is harder to market and better for the person paying.
The Root Cause Consultation, with Dr Pratiksha G Gandhi MD, Preventive Heartcare Expert, reviews your health history, your current medical care, your prior testing, and your family history. Sometimes that ends in a referral for imaging. Often it ends in working on the cholesterol, blood pressure, and metabolic numbers already in front of us, which is the cheaper answer and frequently the right one.
Positioning, stated plainly. Medication is one tool. The bigger opportunity is understanding your actual cardiovascular risk and building a comprehensive prevention plan around it. This article is not anti-statin and not anti-medication.
Boundary. CoCardio® never advises starting, stopping, or changing prescribed medication. Those decisions stay with the physician who prescribed it, and decisions about imaging belong with the physician who will act on the result.
For your privacy, please share results only through our secure booking and intake process, and do not share personal health information in public comments or unsecured messages.
Frequently Asked Questions
Is a carotid ultrasound worth having?
It depends entirely on why. As a way of estimating heart risk when you have no symptoms, no: US guidance rates intima-media thickness measurement as offering no benefit for that. But carotid ultrasound is a real diagnostic test with real uses. If your physician heard a bruit in your neck, if you have had stroke or warning-stroke symptoms, or if you are being followed for a known narrowing, the answer there is yes.
Does more detail about my plaque help me?
It depends on whether anyone can act on it differently. Plaque detail predicts events better than a risk score does, which is unsurprising, since it looks at the disease rather than estimating it. Whether treating according to that detail produces better outcomes is what a trial is testing now, and it has not reported.
Is a whole-body MRI a good idea?
No, on current evidence. Cancer turns up in about 1.5 percent of people scanned who have no symptoms, no study has shown a survival benefit, and incidental findings are common enough that the usual result is an open question, not reassurance.
I have no symptoms. Is there any imaging worth doing?
Yes, for some people. If your calculated risk sits in the borderline or intermediate range and the statin decision is unsettled, a calcium score is recommended and may settle it. A family history of early heart disease is another carve-out in the guidance. Outside situations like those, the societies that perform these tests advise against screening people with no symptoms and no particular reason to be scanned.
Sources and Disclaimer
Sources. Society of Cardiovascular Computed Tomography Choosing Wisely list, 2013. American College of Cardiology Choosing Wisely list, 2012. American College of Radiology Appropriateness Criteria, Asymptomatic Patient at Risk for Coronary Artery Disease, revised 2020 and published as the 2021 update in the Journal of the American College of Radiology. Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High-Risk Patients With Diabetes, the FACTOR-64 randomized trial, JAMA, 2014, with long-term follow-up presented at American Heart Association Scientific Sessions, November 2024. Coronary CT angiography and 10-year outcomes, the SCOT-HEART trial, The Lancet, January 2025. Outcomes of anatomical versus functional testing for coronary artery disease, the PROMISE trial, New England Journal of Medicine, 2015. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, and the 2010 ACCF/AHA guideline it revised, for carotid intima-media thickness. Common carotid intima-media thickness measurements in cardiovascular risk prediction, a meta-analysis, JAMA, 2012. Quantitative coronary imaging consensus statement, Nature Reviews Cardiology, 2025. Medicare local coverage determination L39851, AI-enabled quantitative coronary plaque analysis. Whole-body MRI for opportunistic cancer detection in asymptomatic individuals, a systematic review and meta-analysis, European Radiology, August 2025. Study of Health in Pomerania, incidental whole-body MRI findings. American College of Radiology Statement on Screening Total Body MRI, 2023. 2021 AHA/ACC/Multisociety Guideline for the Evaluation and Diagnosis of Chest Pain, Journal of the American College of Cardiology, 2021. 2024 AHA/ACC/Multisociety Hypertrophic Cardiomyopathy Guideline. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia, JACC, March 2026. Worldwide radiation dose in coronary artery disease diagnostic imaging, INCAPS 4, JAMA, February 2026. CalciumCT.com, Calcium Score Price Index, November 2026 edition (advertised self-pay prices).
This article is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Individual circumstances vary, and decisions regarding cardiovascular care should be made with appropriate healthcare professionals.
CoCardio® services are designed to complement, not replace, emergency care, a cardiologist, primary care physician, cardiac rehabilitation program, prescribed medication, diagnostic testing, or medically recommended procedures.
If you have new, severe, or worsening symptoms, seek appropriate medical attention rather than relying on information provided in this article.




